ITI-007 is an investigational atypical antipsychotic which is currently under development by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia. It is also being developed by Intra-Cellular Therapies for the treatment of bipolar disorder, depression, and sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders. As of September 2015, ITI-007 has passed the first of two phase III clinical trials for schizophrenia.
For research use only. We do not sell to patients.
Name | Lumateperone(ITI-007) |
---|---|
Iupac Chemical Name | 1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one |
Synonyms | Lumateperone;ITI-007;ITI007;ITI 007;ITI-722; ITI722; ITI 722 |
Molecular Formula | C24H28FN3O |
Molecular Weight | 393.50 |
Smile | FC1=CC=C(C=C1)C(CCCN1C[C@@H]2[C@@H](N3CCN(C=4C=CC=C2C34)C)CC1)=O |
InChiKey | HOIIHACBCFLJET-SFTDATJTSA-N |
InChi | InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1 |
CAS Number | 313368-91-1 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | brown oil |
---|---|
Purity | 98% |
Storage | 3 years -20ºCpowder;6 months -80ºC in solvent |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |